Nantahala Capital Management - Q1 2023 holdings

$1.31 Billion is the total value of Nantahala Capital Management's 124 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 28.8% .

 Value Shares↓ Weighting
IWM SellISHARES TRput$180,184,000
-39.2%
1,010,000
-40.6%
13.81%
-28.1%
ESTA BuyESTABLISHMENT LABS HLDGS INC$126,820,118
+6.4%
1,872,160
+3.1%
9.72%
+25.8%
QURE BuyUNIQURE NV$61,837,071
+1.0%
3,070,361
+13.7%
4.74%
+19.4%
IMAX BuyIMAX CORP$58,569,870
+42.8%
3,053,695
+9.2%
4.49%
+68.9%
CASH BuyPATHWARD FINANCIAL INC$55,593,903
-0.8%
1,339,935
+3.0%
4.26%
+17.3%
TA SellTRAVELCENTERS OF AMERICA INC$51,745,165
+12.0%
598,210
-42.0%
3.96%
+32.5%
APEN BuyAPOLLO ENDOSURGERY INC$45,384,208
+12.2%
4,575,021
+12.8%
3.48%
+32.7%
LXFR BuyLUXFER HLDGS PLC$41,646,467
+23.8%
2,464,288
+0.5%
3.19%
+46.3%
IWM SellISHARES TRrussell 2000 etf$34,081,536
-71.7%
191,040
-72.4%
2.61%
-66.6%
KROS SellKEROS THERAPEUTICS INC$31,718,371
-16.6%
742,819
-6.2%
2.43%
-1.4%
PTON BuyPELOTON INTERACTIVE INC$27,865,136
+46.5%
2,457,243
+2.6%
2.14%
+73.2%
TNL  TRAVEL PLUS LEISURE CO$24,636,377
+7.7%
628,4790.0%1.89%
+27.3%
RDVT BuyRED VIOLET INC$23,070,150
-21.4%
1,310,804
+2.8%
1.77%
-7.0%
RMR SellRMR GROUP INCcl a$21,566,840
-9.8%
821,907
-2.9%
1.65%
+6.7%
CDXS BuyCODEXIS INC$21,327,454
+2.0%
5,151,559
+14.8%
1.63%
+20.6%
SNDX  SYNDAX PHARMACEUTICALS INC$20,606,890
-17.0%
975,7050.0%1.58%
-1.9%
APEN  APOLLO ENDOSURGERY INCcall$19,840,000
-0.5%
2,000,0000.0%1.52%
+17.6%
MLHR SellMILLERKNOLL INC$19,100,975
-9.2%
934,033
-6.7%
1.46%
+7.3%
IMTX  IMMATICS N.V$18,964,836
-20.8%
2,748,5270.0%1.45%
-6.4%
HGV SellHILTON GRAND VACATIONS INC$18,225,186
+14.4%
410,200
-0.7%
1.40%
+35.4%
MAX SellMEDIAALPHA INCcl a$16,283,155
+27.5%
1,086,993
-15.3%
1.25%
+50.7%
CBAY SellCYMABAY THERAPEUTICS INC$15,609,698
+10.6%
1,790,103
-20.5%
1.20%
+30.7%
VMD SellVIEMED HEALTHCARE INC$15,386,390
+15.0%
1,592,794
-10.0%
1.18%
+36.0%
GDEN SellGOLDEN ENTMT INC$15,376,826
-9.9%
353,409
-22.5%
1.18%
+6.5%
AUTL SellAUTOLUS THERAPEUTICS PLCspon ads$14,152,936
-4.3%
7,691,813
-1.2%
1.08%
+13.2%
DHX SellDHI GROUP INC$13,247,527
-31.6%
3,414,311
-6.8%
1.02%
-19.2%
AMYT SellAMRYT PHARMA PLCsponsored ads$11,967,628
+14.0%
820,825
-42.9%
0.92%
+34.9%
SellDARIOHEALTH CORP$9,964,250
-5.6%
2,418,507
-2.0%
0.76%
+11.7%
ALTG SellALTA EQUIPMENT GROUP INC$9,939,646
-36.6%
627,107
-47.3%
0.76%
-25.0%
RH  RHcall$9,742,000
-8.8%
40,0000.0%0.75%
+7.8%
HLF SellHERBALIFE NUTRITION LTDcall$9,660,000
-25.2%
600,000
-30.9%
0.74%
-11.6%
RMBL BuyRUMBLEON INC$9,483,864
-1.6%
1,564,994
+5.1%
0.73%
+16.3%
PAYO BuyPAYONEER GLOBAL INC$9,486,663
+23.8%
1,510,615
+39.2%
0.73%
+46.3%
RDI SellREADING INTL INCcl a$9,411,009
+16.8%
2,895,695
-0.4%
0.72%
+38.1%
DXPE  DXP ENTERPRISES INC$9,101,383
-2.3%
338,0900.0%0.70%
+15.4%
PTON SellPELOTON INTERACTIVE INCcall$8,845,200
-18.6%
780,000
-43.0%
0.68%
-3.7%
RH BuyRH$8,782,413
+14.1%
36,060
+25.2%
0.67%
+34.9%
BuyAURA BIOSCIENCES INC$7,827,179
-6.7%
843,446
+5.6%
0.60%
+10.3%
QURE SellUNIQURE NVcall$7,808,278
-71.0%
387,700
-67.4%
0.60%
-65.7%
ZM  ZOOM VIDEO COMMUNICATIONS INcall$7,384,000
+9.0%
100,0000.0%0.57%
+28.9%
DHC BuyDIVERSIFIED HEALTHCARE TR$7,274,660
+166.8%
5,388,637
+27.8%
0.56%
+214.7%
NewCVENT HOLDING CORP$7,064,200845,000
+100.0%
0.54%
ESTA  ESTABLISHMENT LABS HLDGS INCcall$6,774,000
+3.2%
100,0000.0%0.52%
+22.1%
BuyVENTYX BIOSCIENCES INC$6,454,478
+24.6%
192,671
+21.9%
0.50%
+47.3%
CDTX BuyCIDARA THERAPEUTICS INC$6,006,634
+81.8%
4,729,633
+8.3%
0.46%
+115.0%
FBIO SellFORTRESS BIOTECH INC$5,672,658
+8.7%
6,917,876
-13.2%
0.44%
+28.7%
BVS BuyBIOVENTUS INC$5,535,612
-33.1%
5,173,469
+63.3%
0.42%
-20.9%
MDXG BuyMIMEDX GROUP INC$5,214,231
+63.4%
1,529,100
+33.3%
0.40%
+93.2%
CRMT BuyAMERICAS CAR-MART INC$5,074,985
+368.2%
64,070
+327.1%
0.39%
+455.7%
IMAX SellIMAX CORPcall$4,795,000
-85.1%
250,000
-88.6%
0.37%
-82.4%
SSKN  STRATA SKIN SCIENCES INC$4,651,594
+34.0%
4,393,6850.0%0.36%
+58.2%
PWP BuyPERELLA WEINBERG PARTNERS$4,598,167
-7.0%
505,293
+110.7%
0.35%
+10.0%
LYRA  LYRA THERAPEUTICS INC$4,463,868
-36.0%
2,220,8300.0%0.34%
-24.3%
RNG  RINGCENTRAL INCcl a$4,220,867
-13.4%
137,6220.0%0.32%
+2.2%
PNT  POINT BIOPHARMA GLOBAL INC$4,159,829
-0.3%
572,1910.0%0.32%
+18.1%
 PAR TECHNOLOGY CORPnote 2.875% 4/1$4,047,740
+13.5%
3,785,0000.0%0.31%
+34.2%
BuyABEONA THERAPEUTICS INC$4,028,864
-3.8%
1,428,675
+423.8%
0.31%
+14.0%
ILPT NewINDUSTRIAL LOGISTICS PPTYS T$3,869,0721,260,284
+100.0%
0.30%
EHTH NewEHEALTH INC$3,744,000400,000
+100.0%
0.29%
AGS BuyPLAYAGS INC$3,550,068
+212.8%
496,513
+123.1%
0.27%
+267.6%
UTHR NewUNITED THERAPEUTICS CORP DEL$3,516,17215,700
+100.0%
0.27%
IDYA  IDEAYA BIOSCIENCES INC$3,480,280
-24.4%
253,4800.0%0.27%
-10.7%
VKTX NewVIKING THERAPEUTICS INC$3,341,655200,700
+100.0%
0.26%
SellAPTOSE BIOSCIENCES INC$3,186,544
-9.2%
4,978,975
-17.7%
0.24%
+7.0%
MED  MEDIFAST INC$3,110,100
-10.1%
30,0000.0%0.24%
+6.2%
NewJASPER THERAPEUTICS INC$3,056,1021,688,454
+100.0%
0.23%
AAN  THE AARONS COMPANY INC$2,787,606
-19.2%
288,5720.0%0.21%
-4.5%
OPTN  OPTINOSE INC$2,798,500
+4.3%
1,450,0000.0%0.21%
+23.0%
TELA SellTELA BIO INC$2,724,819
-32.1%
256,092
-26.6%
0.21%
-19.6%
ENVA  ENOVA INTL INC$2,365,898
+15.8%
53,2500.0%0.18%
+37.1%
MACK SellMERRIMACK PHARMACEUTICALS IN$2,350,659
-2.3%
191,266
-8.9%
0.18%
+15.4%
KRE NewSPDR SER TRcall$2,193,00050,000
+100.0%
0.17%
SRL SellSCULLY ROYALTY LTD$2,080,497
-14.6%
310,522
-1.7%
0.16%
+0.6%
DYN NewDYNE THERAPEUTICS INC$2,060,940178,901
+100.0%
0.16%
NPCE SellNEUROPACE INC$1,976,292
+205.9%
425,925
-1.8%
0.15%
+259.5%
AVTE BuyAEROVATE THERAPEUTICS INC$1,916,150
+316.5%
95,000
+505.1%
0.15%
+390.0%
SellDISC MEDICINE INC$1,897,310
-38.1%
89,538
-45.0%
0.14%
-27.1%
RILY SellB. RILEY FINANCIAL INC$1,774,943
-24.0%
62,520
-8.5%
0.14%
-9.9%
DAKT  DAKTRONICS INC$1,656,700
+101.1%
292,1870.0%0.13%
+139.6%
ADCT BuyADC THERAPEUTICS SA$1,638,000
+75.3%
840,000
+245.3%
0.13%
+106.6%
BuySOLENO THERAPEUTICS INC$1,496,639
+25.1%
699,364
+15.8%
0.12%
+47.4%
ANEB  ANEBULO PHARMACEUTICALS INC$1,482,112
+19.7%
511,0730.0%0.11%
+42.5%
RZLT BuyREZOLUTE INC$1,477,644
-0.7%
769,606
+7.1%
0.11%
+17.7%
CVNA  CARVANA COcall$1,468,500
+106.5%
150,0000.0%0.11%
+145.7%
IMTXW  IMMATICS N.V*w exp 07/01/202$1,419,985
-42.6%
986,1010.0%0.11%
-31.9%
BuyAVALO THERAPEUTICS INC$1,415,477
-48.1%
808,844
+49.6%
0.11%
-39.0%
EHTH NewEHEALTH INCcall$1,390,896148,600
+100.0%
0.11%
SELB NewSELECTA BIOSCIENCES INC$1,390,0001,000,000
+100.0%
0.11%
 UNICYCIVE THERAPEUTICS INC$1,359,574
+288.9%
647,4160.0%0.10%
+352.2%
TSHA SellTAYSHA GENE THERAPIES INC$1,350,706
-80.1%
1,722,400
-42.6%
0.10%
-76.3%
AGLE SellAEGLEA BIOTHERAPEUTICS INC$1,321,823
-36.3%
4,558,012
-1.2%
0.10%
-24.6%
SellAKUMIN INC$1,283,062
-19.1%
1,886,856
-14.5%
0.10%
-4.9%
WNC SellWABASH NATL CORPput$1,229,500
-18.4%
50,000
-25.0%
0.09%
-4.1%
NewSTRUCTURE THERAPEUTICS INCsponsored ads$1,189,50050,000
+100.0%
0.09%
CYTK BuyCYTOKINETICS INC$1,055,700
+379.8%
30,000
+524.7%
0.08%
+478.6%
SRTS NewSENSUS HEALTHCARE INC$964,100185,048
+100.0%
0.07%
ACER SellACER THERAPEUTICS INC$912,571
-70.3%
1,203,126
-1.9%
0.07%
-64.8%
SCYX NewSCYNEXIS INC$900,000300,000
+100.0%
0.07%
SGRP BuySPAR GROUP INC$898,586
+28.4%
696,578
+29.4%
0.07%
+53.3%
LNDC NewLIFECORE BIOMEDICAL INC$734,992194,700
+100.0%
0.06%
AMRX NewAMNEAL PHARMACEUTICALS INC$695,000500,000
+100.0%
0.05%
NewAYTU BIOPHARMA INC$608,346271,595
+100.0%
0.05%
IDWM SellIDW MEDIA HLDGS INCcl b$592,226
-24.6%
822,537
-1.6%
0.04%
-11.8%
ANGN SellANGION BIOMEDICA CORP$540,509
-35.5%
982,743
-4.9%
0.04%
-24.1%
SellHYPERFINE INC$530,520
+15.9%
368,417
-32.4%
0.04%
+36.7%
KROS SellKEROS THERAPEUTICS INCcall$525,210
-73.9%
12,300
-70.6%
0.04%
-69.2%
NewEBET INC$438,3191,065,432
+100.0%
0.03%
SellLUCID DIAGNOSTICS INC$376,796
-0.9%
261,664
-6.4%
0.03%
+16.0%
TACT SellTRANSACT TECHNOLOGIES INC$376,284
-9.4%
60,789
-7.5%
0.03%
+7.4%
SellJOURNEY MED CORP$333,400
-23.2%
212,357
-6.0%
0.03%
-7.1%
CUE  CUE BIOPHARMA INC$333,070
+25.3%
93,2970.0%0.03%
+52.9%
XGN SellEXAGEN INC$322,250
-8.4%
132,613
-9.5%
0.02%
+8.7%
BMTX SellBM TECHNOLOGIES INC$278,826
-82.6%
79,212
-74.3%
0.02%
-79.8%
NewEARGO INC$252,72954,002
+100.0%
0.02%
CRIS SellCURIS INC$137,446
-68.6%
230,614
-71.0%
0.01%
-60.7%
IMAC SellIMAC HLDGS INC$148,731
-36.5%
1,040,075
-11.4%
0.01%
-26.7%
RFL  RAFAEL HLDGS INC$112,651
-17.1%
72,6780.0%0.01%0.0%
NewLUCY SCIENTIFIC DISCOVERY IN$105,38095,800
+100.0%
0.01%
FULC SellFULCRUM THERAPEUTICS INC$60,904
-98.3%
21,370
-95.7%
0.01%
-97.9%
GAIA NewGAIA INC NEWcl a$64,34023,144
+100.0%
0.01%
CBIO SellCATALYST BIOSCIENCES INC$33,209
-85.6%
160,430
-63.4%
0.00%
-80.0%
 GUARDFORCE AI CO LTD*w exp 10/01/202$30,856
+900.5%
154,2050.0%0.00%
 TC BIOPHARM HOLDINGS PLC*w exp 02/08/202$23,506
+11.7%
235,2940.0%0.00%
+100.0%
 QUALTEK SERVICES INC*w exp 02/14/202$2,921
-26.2%
96,2440.0%0.00%
HERAW ExitFTAC HERA ACQUISITION CORP*w exp 02/28/202$0-222,949
-100.0%
0.00%
SFT ExitSHIFT TECHNOLOGIES INCcl a$0-200,000
-100.0%
-0.00%
ExitKINTARA THERAPEUTICS INC$0-11,901
-100.0%
-0.01%
ExitCYREN LTD$0-116,214
-100.0%
-0.01%
SGU ExitSTAR GROUP L Punit ltd partnr$0-12,681
-100.0%
-0.01%
IDN ExitINTELLICHECK INC$0-124,594
-100.0%
-0.02%
NAUT ExitNAUTILUS BIOTECHNOLOGY INC$0-289,845
-100.0%
-0.03%
LQDA ExitLIQUIDIA CORPORATION$0-146,792
-100.0%
-0.06%
DS ExitDRIVE SHACK INC$0-6,500,000
-100.0%
-0.07%
VRM ExitVROOM INCcall$0-1,500,000
-100.0%
-0.10%
ExitWEBER INCcl a$0-500,000
-100.0%
-0.26%
PRDO ExitPERDOCEO ED CORPput$0-500,000
-100.0%
-0.45%
CNCE ExitCONCERT PHARMACEUTICALS INC$0-1,732,388
-100.0%
-0.66%
PAYA ExitPAYA HOLDINGS INC$0-2,472,352
-100.0%
-1.26%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

About Nantahala Capital Management

Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.

Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.

Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.

Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ISHARES TR42Q3 202327.2%
CODEXIS INC42Q3 20233.9%
PATHWARD FINANCIAL INC35Q3 20236.3%
SCIENTIFIC GAMES CORP34Q3 20225.3%
DOVER MOTORSPORTS INC34Q3 20210.5%
GOLDEN ENTMT INC33Q3 20232.1%
QAD INC32Q3 20212.6%
SCIENTIFIC GAMES CORP31Q4 20217.7%
DOLBY LABORATORIES INC31Q4 20205.6%
LINCOLN EDL SVCS CORP31Q4 20210.7%

View Nantahala Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
Nantahala Capital Management Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AYTU BIOPHARMA, INCJune 16, 20231,086,81219.7%
Acer Therapeutics Inc.February 14, 20231,226,1917.5%
Aeglea BioTherapeutics, Inc.February 14, 20234,611,3027.5%
AKUMIN INC.February 14, 20232,206,9602.5%
ALTA EQUIPMENT GROUP INC.February 14, 20231,188,9853.7%
Apollo Endosurgery, Inc.February 14, 20234,056,6279.9%
Autolus Therapeutics plcFebruary 14, 20237,782,0184.7%
Bioventus Inc.February 14, 20233,168,5745.1%
CATALYST BIOSCIENCES, INC.February 14, 2023438,0551.4%
Drive Shack Inc.February 14, 20236,500,0007.0%

View Nantahala Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
42024-03-21
42024-03-15
SC 13G2024-03-11
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Nantahala Capital Management's complete filings history.

Compare quarters

Export Nantahala Capital Management's holdings